Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Median Technologies
< Previous
1
2
Next >
Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis® LCS
July 01, 2025
From
Median Technologies
Via
Business Wire
Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025
May 27, 2025
From
Median Technologies
Via
Business Wire
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
May 14, 2025
From
Median Technologies
Via
Business Wire
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
May 12, 2025
From
Median Technologies
Via
Business Wire
Median Technologies Reports Full-year 2024 Financial Results
April 29, 2025
From
Median Technologies
Via
Business Wire
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
April 24, 2025
From
Median Technologies
Via
Business Wire
eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study
March 31, 2025
From
Median Technologies
Via
Business Wire
Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference
February 26, 2025
From
Median Technologies
Via
Business Wire
Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
February 24, 2025
From
Median Technologies
Via
Business Wire
Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
February 03, 2025
From
Median Technologies
Via
Business Wire
Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook
January 31, 2025
From
Median Technologies
Via
Business Wire
Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU
January 24, 2025
From
Median Technologies
Via
Business Wire
Median Technologies: Financial Communications Schedule for the First Half of 2025
January 14, 2025
From
Median Technologies
Via
Business Wire
Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024
November 26, 2024
From
Median Technologies
Via
Business Wire
Median Technologies Hosted Insightful Key Opinion Leader (KOL) Webinar on eyonis™ Lung Cancer Screening (LCS) REALITY Data
November 07, 2024
From
Median Technologies
Via
Business Wire
Median Technologies to Host Key Opinion Leader (KOL) Webinar on AI and Lung Cancer Screening
October 30, 2024
From
Median Technologies
Via
Business Wire
Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results
October 24, 2024
From
Median Technologies
Via
Business Wire
Median Technologies to Attend and Present at the ESMO Congress 2024, Being Held in Barcelona, Spain, from Sept 13-17, 2024
September 11, 2024
From
Median Technologies
Via
Business Wire
Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software as medical device at the IASLC 2024 World Conference on Lung Cancer
September 04, 2024
From
Median Technologies
Via
Business Wire
Median Technologies to host two webcasts on September 5, 2024
September 02, 2024
From
Median Technologies
Via
Business Wire
Median Technologies Announces Pivotal REALITY Study of Its eyonis™ LCS Lung Cancer Diagnostic Met All Primary and Secondary Endpoints
August 29, 2024
From
Median Technologies
Via
Business Wire
Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery
August 06, 2024
From
Median Technologies
Via
Business Wire
Median Technologies Reports Record iCRO Backlog, eyonis™ LCS On-Track for Standalone Pivotal Study Readout in August
July 18, 2024
From
Median Technologies
Via
Business Wire
Median Technologies: Disclosure of total number of voting rights and number of shares in the capital as of May 31st, 2024
June 07, 2024
From
Median Technologies
Via
Business Wire
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 19, 2024
June 03, 2024
From
Median Technologies
Via
Business Wire
Median Technologies to Participate in the 2024 ASCO Annual Meeting, May 31 - June 4, 2024, McCormick Place, Chicago, IL, USA
May 29, 2024
From
Median Technologies
Via
Business Wire
Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company
May 21, 2024
From
Median Technologies
Via
Business Wire
Median Technologies Reports Full-year 2023 Financial Results and Provides First Quarter 2024 Financial Information
April 25, 2024
From
Median Technologies
Via
Business Wire
Median Technologies to Participate in the TD Cowen’s 44th Annual Health Care Conference
February 29, 2024
From
Median Technologies
Via
Business Wire
Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria
February 26, 2024
From
Median Technologies
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.